On March 18, 2024, an reveiw articles on cancer screening by a third-party research team (Romania) was published in “Cancers”, an oncology journal published by Switzerland-based MDPI.
The article is entitled “Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening”.
The paper mainly summarizes the latest research results and future prospects of MCED testing. It also discusses the possibility of early cancer detection in the asymptomatic stage, high-cost performance, and minimally invasive cancer test screening.
Several papers on N-NOSE are cited in the article, and N-NOSE is evaluated as an innovative and highly sensitive cancer screening test:
With the observation that C. elegans is attracted to urine from cancer patients, but avoids urine from healthy persons, a team led by Hirotsu et al. perfected an innovative, highly sensitive cancer screening test called N-Nose, which has been available in Japan since 2020.[18]
It is important to mention that the N-Nose behavioral assay has been thoroughly evaluated in clinical studies with large cohorts of patients, showing reliable results. Also, the results have been replicated at other prestigious institutions in the US and Italy.[18]
References
Cancers 2024, 16(6), 1191; https://doi.org/10.3390/cancers16061191
We are pleased to announce the publication of an original article in the international journal, Journal of Clinical and Translational Research, . . .
2025.05.09Japan’s Ministry of Health, Labour and Welfare (MHLW) recently updated its Guidelines for New Business Activities in the Healthy Life Expectancy . . .
2025.04.08The original research article demonstrating the efficacy of N-NOSE in detecting blood cancers (also known as hematological malignancies) has bee . . .
2025.03.31